Predicting Pathological Complete Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy With MR Radiomics Method
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Locally Advanced Rectal Cancer
- Sponsor
- Sun Ying-Shi
- Enrollment
- 538
- Locations
- 1
- Primary Endpoint
- Pathological complete response(pCR)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
This study plans to construct a MR radiomics model for predicting pathological complete response(pCR) to neoadjuvant chemoradiotherapy(CRT) in locally advanced rectal cancer(LARC) patients.
Detailed Description
We propose to develop and validate a radiomics model for individualized pCR evaluation after CRT in patients with LARC. We plan to use both pre- and post-CRT MRI data to construct the predictive radiomics model for evaluating if LARC patients achieve pCR after CRT. The ultimate aim is to select appropriate LARC patients for omission of surgery.
Investigators
Sun Ying-Shi
Director
Peking University Cancer Hospital & Institute
Eligibility Criteria
Inclusion Criteria
- •pathologically proved rectal cancer
- •locally advanced rectal cancer (≥T3 or N+)
- •a distance less than 12cm between the lower edge of tumor and the anal margin
- •no evidence of distant metastases
- •no prior anti-cancer therapy before treatment
- •scheduled to receive preoperative CRT
Exclusion Criteria
- •history or concurrent of other malignancy
- •incomplete preoperative CRT
- •failed to receive surgery or unavailable pCR assessment
- •poor quality of MR images for measurement
- •patient quit
Outcomes
Primary Outcomes
Pathological complete response(pCR)
Time Frame: within one week after surgery
Pathological complete response was defined as the absence of viable tumor cells in the primary tumor and lymph nodes.